Back to Search Start Over

Risk factors for potentially inappropriate medication use in older adults: a cohort study.

Authors :
de Araújo NC
Silveira EA
Mota BG
Guimarães RA
Modesto ACF
Pagotto V
Source :
International journal of clinical pharmacy [Int J Clin Pharm] 2022 Oct; Vol. 44 (5), pp. 1132-1139. Date of Electronic Publication: 2022 Jul 27.
Publication Year :
2022

Abstract

Background: Much of the knowledge on the use of potentially inappropriate medications (PIM) in older adults is derived from cross-sectional studies, with little known about the risk factors over time.<br />Aim: Longitudinal analysis was applied to estimate the occurrence and risk factors of PIM use among older adults in a 10-year follow-up.<br />Method: Longitudinal study with 418 older adult residents of a capital city of Central-West Brazil. The PIM were classified according to the Beers criteria 2019. The usage rate was calculated at baseline (2008) and at the 10-year follow-up moment (2018). Analysis of predictors (sociodemographic, self-rated health, hospitalization, number of comorbidities, polypharmacy, diabetes, hypertension, hypercholesterolemia and nutritional status) was performed using Generalized Estimating Equation (GEE) models.<br />Results: Mean age at baseline was 70.6 years (SD 7.1) and 76% were women; 221 older adults took part in the follow up. The rate of PIM use was 50.4% at baseline and 57.5% at the 10-year follow-up. Multiple analysis showed that PIM use in the cohort was statistically higher in the older adults with a history of hospitalization (RR <subscript>adj</subscript> 1.20; 95% CI 1.01-1.40), with three or more diseases (RR <subscript>adj</subscript> 1.41; 95% CI 1.14-1.74), with polypharmacy (RR <subscript>adj</subscript> 1.81; 95% CI 1.47-2.24) and with diabetes mellitus (RR <subscript>adj</subscript> 1.24; 95% CI 1.05-1.47).<br />Conclusion: A high level of potentially inappropriate medication use was observed, reaching 50% of the older adults, with a 7% increase in the prevalence over the 10-year follow-up period. Hospitalization, multimorbidities, polypharmacy and diabetes mellitus were associated with the use of these medications. Interventions for surveillance of the deprescribing process need to be encouraged to avoid potential harm caused by the use of medications.<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)

Details

Language :
English
ISSN :
2210-7711
Volume :
44
Issue :
5
Database :
MEDLINE
Journal :
International journal of clinical pharmacy
Publication Type :
Academic Journal
Accession number :
35896907
Full Text :
https://doi.org/10.1007/s11096-022-01433-4